Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide for AK and SCC prevention in organ transplant recipients
NCT00829192Phase 2Unknown
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Nov 2007
- Primary completion
- Jul 2012
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of Afamelanotide in actinic keratosis (AK), squamous cell carcinoma (SCC), sponsored by Clinuvel Pharmaceuticals. Status: unknown.
02
Drugs
Afamelanotide
03
Conditions
actinic keratosis (AK)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT00829192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00829192.